Videos

Optune Lua video library

See below for educational videos about Optune Lua.

How Optune Lua Expands Treatment Options for mNSCLC

Dr Simon Khagi discusses how Optune Lua provides a noninvasive approach for patients with limited treatment options.

Now playing

How Optune Lua Expands Treatment Options for mNSCLC

Dr Simon Khagi discusses how Optune Lua provides a noninvasive approach for patients with limited treatment options.

Identifying the Patient

Dr Simon Khagi discusses patient eligibility for Optune Lua, including the prime patient setting for treatment.

Introducing Optune Lua to Patients

Dr Simon Khagi discusses introducing treatment with Optune Lua to patients and caregivers.

Empowering Patients With More Options

Dr Simon Khagi discusses how Optune Lua expands treatment options and empowers patients.

Integrating Optune Lua Into Practice

Dr Simon Khagi discusses his experience of incorporating treatment with Optune Lua into his clinical practice.

Case Study: A Real Patient Example

Dr Simon Khagi discusses a patient case of adding Optune Lua to maintenance IO at slow progression after a platinum-based regimen.

Mechanism of Action

Watch this short video to learn the science behind Tumor Treating Fields (TTFields).

Introducing Optune Lua to Patients

Dr Simon Khagi discusses introducing treatment with Optune Lua to patients and caregivers.

Now playing

Introducing Optune Lua to Patients

Dr Simon Khagi discusses introducing treatment with Optune Lua to patients and caregivers.

How Optune Lua Expands Treatment Options for mNSCLC

Dr Simon Khagi discusses how Optune Lua provides a noninvasive approach for patients with limited treatment options.

Identifying the Patient

Dr Simon Khagi discusses patient eligibility for Optune Lua, including the prime patient setting for treatment.

Empowering Patients With More Options

Dr Simon Khagi discusses how Optune Lua expands treatment options and empowers patients.

Integrating Optune Lua Into Practice

Dr Simon Khagi discusses his experience of incorporating treatment with Optune Lua into his clinical practice.

Case Study: A Real Patient Example

Dr Simon Khagi discusses a patient case of adding Optune Lua to maintenance IO at slow progression after a platinum-based regimen.

Mechanism of Action

Watch this short video to learn the science behind Tumor Treating Fields (TTFields).

Empowering Patients With More Options

Dr Simon Khagi discusses how Optune Lua expands treatment options and empowers patients.

Now playing

Empowering Patients With More Options

Dr Simon Khagi discusses how Optune Lua expands treatment options and empowers patients.

How Optune Lua Expands Treatment Options for mNSCLC

Dr Simon Khagi discusses how Optune Lua provides a noninvasive approach for patients with limited treatment options.

Identifying the Patient

Dr Simon Khagi discusses patient eligibility for Optune Lua, including the prime patient setting for treatment.

Introducing Optune Lua to Patients

Dr Simon Khagi discusses introducing treatment with Optune Lua to patients and caregivers.

Integrating Optune Lua Into Practice

Dr Simon Khagi discusses his experience of incorporating treatment with Optune Lua into his clinical practice.

Case Study: A Real Patient Example

Dr Simon Khagi discusses a patient case of adding Optune Lua to maintenance IO at slow progression after a platinum-based regimen.

Mechanism of Action

Watch this short video to learn the science behind Tumor Treating Fields (TTFields).

Find the answers to frequently asked questions about Optune Lua

Review FAQs

Novocure is NOT permitted to provide medical advice to patients. All patients with medical questions will be referred back to their healthcare provider.

Important Safety Information 

Contraindications 

Do not use Optune Lua® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device. 

 

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions 

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer). 

 

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established. 

 

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia. 

 

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer. 

 

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

 

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen. 

 


Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.

Important Safety Information 

Contraindications 

Do not use Optune Lua® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device. 

 

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions 

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer). 

 

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established. 

 

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia. 

 

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer. 

 

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

 

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen. 

 


Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.

Novocure Websites

This website is intended for US healthcare professionals seeking information on Optune Lua.

 

 

 

 

©2026 Novocure GmbH. All Rights Reserved. 

Optune Lua, MyNovocure, MyLink, and Novocure are trademarks of Novocure GmbH.

US-OPL-00070 v4.0 February 2026